Kisspeptin
Kisspeptin-10 / Metastin
Kisspeptin (Kisspeptin-10 / Metastin) is a hormonal & sexual research compound. Hypothalamic peptide that stimulates GnRH release, driving LH/FSH and downstream testosterone — upstream of the whole HPG axis.
Kisspeptin quick facts
| Reported research dose | 50mcg-200mcg |
| Route | Subq |
| Frequency | 1-2x Daily |
| Half-life | ~28-30 min |
| Forms | Injectable |
| Evidence level | Human research |
Works upstream of HCG — stimulates your own signaling rather than replacing it. Elegant for fertility/libido.
How Kisspeptin works
Hypothalamic peptide that stimulates GnRH release, driving LH/FSH and downstream testosterone — upstream of the whole HPG axis.
Proposed benefits
Upstream stimulation of the reproductive hormone axis (LH/FSH, testosterone).
Where to get Kisspeptin
Buy Kisspeptin at Flawless Compounds →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Kisspeptin
Graded by what exists behind each claim.
✅ Clinically validated
- Genuine human trials, mostly out of Imperial College London. Kisspeptin-54 infusion reliably triggers LH and FSH release in men and women, and has been trialed as a trigger for oocyte maturation in IVF — where it produced substantially less ovarian hyperstimulation syndrome than the standard hCG trigger, which is a real clinical advantage.
- Further trials showed effects on limbic brain activity and sexual response in men with hypoactive sexual desire.
📊 Correlative data
- Limited community use relative to its evidence base — it is one of the better-studied peptides here and one of the least used, largely because the half-life makes practical dosing awkward.
🧪 Theoretical / extrapolated
- Kisspeptin sits upstream of the entire reproductive axis — it drives GnRH release, which drives LH and FSH, which drive testosterone or estrogen. It is the master switch, and loss-of-function mutations cause failure to enter puberty.
- Acting that far upstream predicts the appeal and the limit: the whole axis stays under its own feedback control, and a very short half-life means continuous administration paradoxically desensitizes the system rather than driving it harder.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Kisspeptin actually does
Kisspeptin sits one step upstream of everything the gonadorelin page is about, and that single positional fact is the whole argument for it. A GnRH agonist acts on the pituitary and can therefore desensitize the pituitary. Kisspeptin acts on the GnRH neuron, so the pituitary continues to see whatever pattern the hypothalamus decides to send.
The peptide and the receptor. The KISS1 gene product is processed to a 54-residue peptide and to shorter C-terminal fragments; the decapeptide kisspeptin-10 retains full activity and is what is usually studied. It is an RFamide — the C-terminus is arginine-phenylalanine-amide, and that motif is what the receptor reads. The receptor is KISS1R, formerly GPR54, a Gq/11-coupled GPCR expressed on GnRH neurons: phospholipase C, inositol trisphosphate, calcium, depolarization, GnRH release Koysombat 2025.
Human genetics establishes that this is not optional. Loss-of-function mutations in KISS1R cause normosmic idiopathic hypogonadotropic hypogonadism: puberty does not start, and the pituitary and gonads are structurally normal. An intact axis with a broken upstream trigger produces exactly the phenotype of no axis at all, which is as clean a demonstration of a necessary step as endocrinology contains Patel 2023.
The circuit that actually generates the pulse, and it is a three-transmitter machine. Kisspeptin neurons in the arcuate nucleus co-express neurokinin B and dynorphin — the KNDy neurons. Neurokinin B acting on NK3 receptors is the accelerator that recruits the population into synchrony; dynorphin acting on kappa-opioid receptors is the brake that terminates each burst; kisspeptin is the output that reaches the GnRH neuron. An oscillator built from a mutually exciting population and a delayed self-inhibition is a standard way to build a clock, and this is the reproductive one Koysombat 2025 Mills 2022.
That circuit is already a drug target, which is the strongest evidence it is real. Neurokinin-3 receptor antagonists treat menopausal vasomotor symptoms by damping the same KNDy population, and the translation of kisspeptin and neurokinin B biology into therapy is now its own review literature Mills 2022. A licensed drug acting on one node of a circuit is the best possible argument that the circuit exists as described.
Why the half-life is minutes and why that is expected. The card gives 28 to 30 minutes for kisspeptin-10. A decapeptide in plasma is exposed to endopeptidases and to renal filtration; the C-terminal amide protects one end and nothing protects the middle. As with GnRH, a pulse-generating signal is not supposed to persist.
Cell, rodent, human — and where it stops
Step one, genetics and receptor pharmacology: settled. KISS1R loss of function, Gq coupling, and the KNDy architecture Koysombat 2025 Patel 2023.
Step two, humans, and unusually the human work came early. Kisspeptin has been administered to people in physiological studies for close to two decades, and the clinical applications of the kisspeptin-GnRH pathway in female reproduction now have their own review Hu 2022. The endpoint in most of that work is gonadotropin release measured over minutes to hours — a mechanistic endpoint, not a clinical one, and it is important to say which is which.
Step three, the application closest to becoming real, and it is diagnostic rather than therapeutic. Kisspeptin is being developed as a test of hypothalamic dysfunction in pubertal and reproductive disorders Pierret 2025. The logic is elegant: if the GnRH neuron responds to kisspeptin, the problem is upstream of it; if it does not, the problem is the neuron or below. That distinction currently requires inference and time, and a single stimulation test would replace both.
Step four, the therapeutic use where a mechanism argument is strongest. In assisted reproduction the final oocyte maturation trigger is conventionally hCG, which acts at the LH receptor and persists for days — and that persistence is a driver of ovarian hyperstimulation syndrome. A kisspeptin trigger induces the endogenous LH surge, which is shaped and terminated by the person's own physiology Hu 2022. The mechanism predicts less hyperstimulation, and that is a testable, clinically meaningful prediction rather than a hopeful one.
Where the chain breaks. (1) Most human administration studies are acute: a bolus or a short infusion with gonadotropin sampling. Chronic administration is where the interesting question is and where the data mostly is not. (2) KISS1R is a GPCR and continuous agonism can desensitize it — the same trap the GnRH receptor has, moved one synapse upstream, and it means the no-desensitization advantage is about the pituitary, not about immunity from desensitization in general. (3) Kisspeptin neurons also signal outside reproduction, including in circuits studied for mood and behavior Mills 2022, so an exogenous agonist is not confined to the axis. (4) Almost none of this work is in the population that buys the peptide.
What would have to be true, and how you would know it was not
Three predictions. The first is the acute test, the second is the chronic question, and the third is the one that would falsify the upstream advantage.
1. If KISS1R is engaged, gonadotropins rise within an hour — and that is a test, not a treatment. LH/FSH before and 30 to 60 minutes after administration is the acute response, and it is exactly the design being formalized as a diagnostic Pierret 2025. No LH response means the GnRH neuron is not answering, and that finding points downstream rather than suggesting a higher dose.
2. The downstream read-out lags by weeks, as with any axis intervention. Total testosterone and free testosterone in men, estradiol and cycle timing in women, at baseline and 8 to 12 weeks. Prolactin belongs in the same panel, because a raised prolactin suppresses the axis at the hypothalamic level and would blunt any kisspeptin effect — which makes it a confounder that has to be excluded before a null result means anything.
3. The falsification test for the whole upstream argument. The claim is that acting above the pituitary avoids the downregulation a GnRH agonist causes. That predicts something specific and checkable: on a stable schedule, the LH response measured at week 1 and again at week 8 should be similar. If the week-8 response is markedly smaller, KISS1R has desensitized and the advantage over a GnRH agonist has evaporated — and that is a result that would matter, because the entire rationale for choosing kisspeptin over gonadorelin rests on it.
What nobody has tested yet
Four experiments nobody has run, and the first is the one the entire consumer interest depends on.
Nobody has run a chronic kisspeptin trial in men with a suppressed axis. The human record is dominated by acute administration with gonadotropin endpoints Koysombat 2025 Hu 2022. Whether repeated dosing over months restores an axis suppressed by exogenous androgen — which is why people buy it — has never been measured.
Nobody has mapped KISS1R desensitization in humans. The receptor is a Gq-coupled GPCR and every such receptor has arrestin machinery. The experiment is a repeated stimulation test at intervals on stable dosing, and it would settle the upstream advantage in one study.
Nobody has tested kisspeptin against hCG as a trigger with a hard hyperstimulation endpoint at scale. The mechanism predicts a clear benefit Hu 2022 and it is exactly the kind of prediction that turns out to be right or wrong in a large randomized trial rather than in an argument.
Nobody has separated the reproductive effect from the behavioral one. Kisspeptin signaling appears in circuits studied for mood, attraction and behavior as well as in the axis Mills 2022. A trial measuring validated mood and behavioral instruments alongside gonadotropins, in the same people, would say whether the two effects can be separated by dose or route — and it has not been done.
Kisspeptin — its own safety story, not its class's
Kisspeptin is not an approved drug anywhere. Its human record is physiological research and early clinical development Patel 2023 Pierret 2025, and the class block above does not describe a research peptide with no label.
The acute tolerability in research settings has been reasonable, and that is a narrow statement. Acute administration in supervised studies has not produced dramatic adverse effects Koysombat 2025. That is a statement about single doses in monitored volunteers, not about months of self-administration, and treating the first as evidence for the second is the specific error this page exists to prevent.
The predictable risk is doing exactly what it is designed to do. Kisspeptin raises gonadotropins and therefore sex steroids. In anyone with a hormone-sensitive condition — endometriosis, uterine fibroids, a hormone-receptor-positive malignancy, or untreated prostate disease — that is a hazard rather than a benefit, and it follows from the mechanism rather than from any reported event.
The receptor is not only in the axis. KISS1R and its neurons appear in circuits studied for mood and behavior Mills 2022. An exogenous agonist reaching those circuits has no characterized effect profile in chronic use, and the honest statement is that nobody has looked.
Product identity is a specific problem for this peptide. Kisspeptin-10 is a decapeptide whose activity depends on an intact C-terminal RF-amide. A synthesis that fails to amidate the C-terminus produces a peptide that weighs almost the same and does almost nothing, and no purity figure on a certificate of analysis distinguishes those two outcomes unless the analysis was designed to. This is a case where a null personal result is at least as likely to be a chemistry failure as a biology one.
What this page will not do. Print a dose or a schedule. The acute pharmacology is real and well described Koysombat 2025; the chronic use is unstudied; and the honest summary is that kisspeptin is a beautifully characterized physiological signal with no clinical evidence for the way it is being sold.
Sources read for this page
- Koysombat K, et al. Kisspeptin and Neurokinin B: roles in reproductive health. Physiological Reviews 2025 · PMID 39813600
- Patel B, et al. The emerging therapeutic potential of kisspeptin and neurokinin B. Endocrine Reviews 2023 · PMID 37467734
- Pierret ACS, et al. Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders. Andrology 2025 · PMID 39834030
- Mills EG, et al. Invited review: Translating kisspeptin and neurokinin B biology into new therapies for reproductive health. Journal of Neuroendocrinology 2022 · PMID 36262016
- Hu KL, et al. Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction. Reproductive Biology and Endocrinology 2022 · PMID 35606759
Kisspeptin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on the top of the reproductive axis, and which direction they push depends on how they are given. hCG and gonadorelin stimulate; kisspeptin stimulates upstream of GnRH. Continuous GnRH agonism (triptorelin) paradoxically SUPPRESSES after an initial flare, because sustained signaling desensitizes the receptor. Cetrorelix is a straightforward antagonist and suppresses immediately.
- The predicted harm follows the direction: stimulation raises testosterone and estradiol together, so aromatization-driven effects arrive with it. Suppression produces a hypogonadal state — low libido, fatigue, mood change, and bone loss if prolonged.
- The initial FLARE on a GnRH agonist is the specific thing to know about: hormones rise sharply before they fall, and symptoms can transiently worsen.
What has actually been reported
- hCG is well characterized in fertility medicine — gynecomastia and fluid retention from the estradiol rise are the common complaints.
- GnRH agonist flare is documented and clinically managed in oncology with an antiandrogen during the first weeks.
How to reduce the risk
Same mechanism as the prediction.
- If using hCG alongside an androgen to preserve testicular function, lower and more frequent beats large and infrequent — the estradiol spike tracks the dose size.
- Anything suppressing the axis for more than a few months needs a bone density conversation, not just a hormone panel.
What it does to your bloodwork
A fact about the assay.
- LH and FSH, total and free testosterone, sensitive estradiol (these raise it more than people expect), and a semen analysis if fertility is the reason you are running it.
Don't run this if
- You have a hormone-sensitive cancer, unless this is being directed by an oncologist — in which case it is their protocol, not one to self-manage.
The honest unknown
- Kisspeptin analogs are early in human study. The axis effect is real and well demonstrated acutely; the consequences of repeated long-term use are not established.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Kisspeptin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Kisspeptin moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Kisspeptin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Kisspeptin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| LH & FSH | Kisspeptin acts directly upstream of these two |
| Total Testosterone | The downstream result |
| Estradiol, Sensitive (LC/MS-MS) | The other downstream result |
| Prolactin | High prolactin suppresses the same axis and confounds everything |
The “Low T? Rule Out the Reversible Causes First” panel covers these in one order — 11 markers, $211.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Kisspeptin — frequently asked questions
What is Kisspeptin?
Kisspeptin (Kisspeptin-10 / Metastin) is a hormonal & sexual research compound. Hypothalamic peptide that stimulates GnRH release, driving LH/FSH and downstream testosterone — upstream of the whole HPG axis.
Is the full Kisspeptin protocol on this page?
The reported research dose is on this page, along with how Kisspeptin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Kisspeptin?
Kisspeptin has an approximate half-life of ~28-30 min, which is part of what determines how often it's dosed.
What's the evidence behind Kisspeptin?
Current evidence level: Human research. Kisspeptin is offered for research purposes only and is not an approved medicine.
Kisspeptin inside a finished plan
One arm of 4 Protocol Blueprints, free to read in full.
What Kisspeptin is used for
Kisspeptin appears under 3 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Kisspeptin is the androgen-signaling arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.